Please login to the form below

insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk preps for speedy oral GLP-1 drug filing

Group sales barely moved in 2018 compared to the prior year, coming in at 112bn krone, with the GLP-1 portfolio’s growth offsetting declines in insulin products. ... 10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a

Latest news

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation
Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Victoza’s performance meant that Novo Nordisk was able to weather the pressure in the insulins market, which kept its overall insulin sales flat at DKK 14.66bn. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

insulin degludec/liraglutide).
Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine. Novo Nordisk has filed new data to the FDA showing its long-acting insulin Tresiba is less likely to cause low blood sugar ... The Danish drugmaker wants the results of the DEVOTE trial -
Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo

More from news
Approximately 12 fully matching, plus 55 partially matching documents found.

Latest Intelligence

Interview: Peter Meeus, Novo Nordisk

Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director or Senior Account Director: Salary TBC

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Consultant: competitive salary

Account Manager– Medical Communications: (Negotiable - depending on experience)

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Vice President: Competitive Salary Offered

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Senior Medical Writer, MedComms Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...